Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
Biohaven issued a press release on March 3, 2025, reporting its financial results for the fourth quarter and full year 2024, as well as reporting recent business developments. Among other items, Biohaven reported a loss of $1.71 per share for the quarter, while analysts were expecting a loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company’s BHV-7000 drug in bipolar mania “did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure”.
Following this news, Biohaven’s stock price fell over 13% on the same day.